Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system. It also offers cardiovascular products; digestive products to regulate intestinal and digestive functions; personal care products for external use, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser. In addition, the company provides weight management products, such as meal replacements and products that increase caloric burn rate. It offers its products under the Nature's Sunshine and Synergy Worldwide brands through its network of independent consultants to customers. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.…
Nature’s Sunshine Announces Partnership with Health and Fitness Expert Peter Nielsen
Nature's Sunshine Products (NASDAQ: NATR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 806 employees.
The shares were at 10.18 USD on 20 November 2026, down 43.2% over 52 weeks. Its 52-week range is 9.376 USD to 28.14 USD: the price is 63.8% below the high and 8.6% above the low.
At a market capitalisation of 176.41M USD, it trades at 12.4 times trailing earnings and 10.8 times forward earnings. The median trailing P/E of its 18 largest Packaged Foods peers is 24.8, a discount of 50% for NATR.
Nature's Sunshine Products reports return on equity of 12.1%, an operating margin of 5.3% and revenue down 9.1% year over year.
It holds more cash than debt, a net cash position of 68.35M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 16.50 USD is 62.1% above the current price. The next earnings report is expected on 16 March 2027.